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The comparison between long acting insulin analogues (LAIA) and human insulin (NPH)
has been investigated for decades, with many randomized controlled trials (RCTs) and sys-
tematic reviews giving mixed results. This overlapping and contradictory evidence has
increased uncertainty on coverage decisions at health systems level.
Aim
To conduct an overview of systematic reviews and update existing reviews, preparing new
meta-analysis to determine whether LAIA are effective for T1D patients compared to NPH.
Methods
We identified systematic reviews of RCTs that evaluated the efficacy of LAIA glargine or
detemir, compared to NPH insulin for T1D, assessing glycated hemoglobin (A1C) and hypo-
glycemia. Data sources included Pubmed, Cochrane Library, EMBASE and hand-search-
ing. The methodological quality of studies was independently assessed by two reviewers,
using AMSTAR and Jadad scale. We found 11 eligible systematic reviews that contained a
total of 25 relevant clinical trials. Two reviewers independently abstracted data.
Results
We found evidence that LAIA are efficacious compared to NPH, with estimates showing a
reduction in nocturnal hypoglycemia episodes (RR 0.66; 95% CI 0.57; 0.76) and A1C (95%
CI 0.23; 0.12). No significance was found related to severe hypoglycemia (RR 0.94; 95% CI
0.71; 1.24).
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Conclusion
This study design has allowed us to carry out the most comprehensive assessment of RCTs
on this subject, filling a gap in diabetes research. Our paper addresses a question that is
important not only for decision makers but also for clinicians.
Introduction
Intensive insulin therapy improves outcomes of patients with type 1 diabetes (T1D). These
improvements include better glycemic control and a reduction in the risk of complications [1–
3], preventing or delaying the progression of chronic microvascular complications in approxi-
mately 50% of cases [1], which makes the treatment more effective. Although the importance
of glycemic control has been known for approximately three decades [4], this control is still
flawed in many countries. For example, glycemic control was unsatisfactory in 87% of Brazil-
ian T1D patients (glycated hemoglobin, A1C > 7%) in 2012 [5]. This scenario has become a
global concern since the number of people living with diabetes has almost quadrupled since
1980 to 422 million adults (6). It is estimated that T1D accounts for between 5 and 10% of all
cases of diabetes (6), and the incidence rate increases by 3% a year [6].
The comparison between insulin analogues and human insulin has been investigated for
decades, with many randomized controlled trials (RCTs) and systematic reviews giving mixed
results [7–11] This contradictory evidence has increased uncertainty on coverage decisions at
health system level. For example, among the five countries with the highest number of people
with T1D (China, India, the USA, Brazil and Russia), only the USA [12] and Russia [13] have
clinical guidelines for T1D patients that include long-acting insulin analogues among the treat-
ment options, under restricted indications.
To deal with the substantial increase in the number of overlapping systematic reviews, guid-
ance on how to conduct overviews of systematic reviews has emerged since the mid-2000s
[14,15]. The purpose of overviews is to summarize evidence, synthesizing results from multiple
systematic reviews into a single, useful document [15,16]. Overviews identify high-quality, reli-
able systematic reviews and explore consistency of findings across reviews [15]. To the best of
our knowledge, this is the first overview on the efficacy of long-acting insulin analogues com-
pared to NPH for T1D. We sought to shed some light on this issue to support decision making
from both clinical and public health perspectives.
In this context of doubt and uncertainty on the recommendations [17,18] we aimed to con-
duct an overview of systematic reviews and also update existing reviews, aggregating clinical
trials published to date and preparing a new meta-analysis to determine whether long-acting
insulin analogues are effective and safe for T1D patients compared to NPH in reduction of
hypoglycemia and maintenance or improvement of glycemic control.
Materials and methods
We performed an overview of systematic reviews of RCTs (guided by the Cochrane Handbook
[15]) on the efficacy of long-acting insulin analogues compared to NPH human insulin for
T1D patients. We also updated systematic reviews included in this overview, by including
RCTs published after publication of the systematic reviews. The protocol for this overview was
registered in the International Prospective Register of Systematic Reviews (PROSPERO) under
number CRD42016047137. We report according to PRISMA guidelines (S1 Checklist).
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Criteria for study selection
We selected systematic reviews of RCTs that evaluated efficacy of long-acting insulin ana-
logues compared to NPH human insulin for T1D patients. The inclusion criteria were: i) a
direct or indirect comparison between long-acting insulin analogues and NPH; ii) T1D
patients regardless age group; iii) results that included at least one of the primary outcomes
related to efficacy (A1C, and general, severe and nocturnal hypoglycemia).
In cases of eligible systematic reviews that included RCTs and other study designs, we
included these reviews if it was possible to extract the RCTs results independently. A similar
procedure was applied for reviews that reported results for type 1 and type 2 diabetes. If sev-
eral publications from the same author or group were identified, the publications were re-
scanned to decide whether the reported reviews or trials were the same. In such cases, the
most recent publication was selected unless the earlier one provided more information. Stud-
ies published as abstracts were included when sufficient information on methods and results
was provided. We restricted our search to English, Spanish and Portuguese systematic reviews
and studies in humans. There was no restriction on year of publication. We included both
Cochrane and non-Cochrane reviews. We excluded studies that assessed pregnant patients,
analyzed only rapid-acting insulin analogues as the intervention, or assessed outcomes other
than A1C and hypoglycemia.
To update the included systematic reviews, we performed a separate search for RCTs assess-
ing long-acting insulin analogues as the intervention compared to NPH human insulin, and
reporting outcomes as A1C (in terms of the difference between the end of study and baseline
or the measures of the baseline and the end of study independently) and hypoglycemia, con-
sidering the categories: general, severe and nocturnal (in terms of number of episodes or rate
of episodes per person-time). Regarding the clinical trials located in the selected systematic
reviews or in the complementary search, we considered only phase III RCTs, classified as
Jadad 2, which compared long-acting insulin analogues to NPH, evaluating the outcomes of
interest for inclusion in meta-analysis.
Data sources and searches
Potentially relevant systematic reviews were identified through a comprehensive and exhaus-
tive search of electronic databases: the Cochrane Library, PubMed and EMBASE. We con-
ducted the first search in February 2015 and the last update in October 2016. We used a filter
for systematic reviews and meta-analyses and for study language when this option was avail-
able at the database searched.
The search strategy was developed using MeSH terms for Pubmed, EMTREE terms for
Embase, and a combination of keywords for Cochrane Library. For example, the full electronic
search strategy used at Pubmed was: ("Diabetes Mellitus, Type 1"[Mesh] OR "Type 1 Diabetes
Mellitus"[tiab] OR "IDDM"[tiab] OR "T1DM"[tiab]) AND (("long-acting insulin analogue"[tiab]
OR (("Analog Sci Fict Sci Fact"[Journal] OR "analog"[All Fields]) AND ("insulin, long-acting"
[MeSH Terms] OR ("insulin"[All Fields] AND "long-acting"[All Fields]) OR "long-acting insuli-
n"[All Fields] OR ("long"[All Fields] AND "acting"[All Fields] AND "insulin"[All Fields]) OR
"long acting insulin"[All Fields])) OR "long-acting analog insulin"[All Fields] OR "basal insulin
analogue"[tiab] OR "basal analog insulin"[All Fields] OR "insulin analog"[All Fields]) OR
("glargine"[tiab] OR "lantus"[tiab] OR "HOE 901"[tiab]) OR ("insulin detemir"[Supplementary
Concept] OR "detemir"[tiab] OR "levemir"[tiab] OR "NN304"[tiab]) OR ("insulin degludec"
[Supplementary Concept] OR "insulin degludec"[tiab] OR "degludec "[tiab])) AND (Meta-Anal-
ysis[ptyp] OR systematic[sb]) AND (English[lang] OR Portuguese[lang] OR Spanish[lang]).
This strategy was slightly adapted for use in EMBASE and Cochrane Library (S1 Table).
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We also performed a separate search to check for RCTs published after the most recent sys-
tematic review included in our overview. We used the following strategy in Pubmed (from 09/
01/2013 to 29/10/2016): ("Diabetes Mellitus, Type 1"[MeSH] OR "Type 1 Diabetes Mellitus"[-
tiab] OR "IDDM"[tiab] OR "T1DM"[tiab]) AND (("long-acting insulin analogue"[tiab] OR
("analog"[All Fields]) AND ("insulin, long-acting"[MeSH Terms] OR ("insulin"[All Fields]
AND "long-acting"[All Fields]) OR "long-acting insulin"[All Fields] OR ("long"[All Fields]
AND "acting"[All Fields] AND "insulin"[All Fields]) OR "long acting insulin"[All Fields])) OR
"long-acting analog insulin"[All Fields] OR "basal insulin analogue"[tiab] OR "basal analog
insulin"[All Fields] OR "insulin analog"[All Fields]) OR ("glargine"[All Fields] AND (Sup-
plementary[All Fields] AND Concept[All Fields]) OR "glargine"[tiab] OR "lantus"[tiab] OR
"HOE 901"[tiab]) OR ("insulin detemir"[All Fields] AND (Supplementary[All Fields] AND
Concept[All Fields]) OR "detemir"[tiab] OR "levemir"[tiab] OR "NN304"[tiab]) OR ("insulin
degludec"[All Fields] AND (Supplementary[All Fields] AND Concept[All Fields]) OR "insulin
degludec"[tiab] OR "degludec"[tiab] OR "tresiba"[tiab])) AND (English[lang] OR Portuguese
[lang] OR Spanish[lang]) AND (Randomized Controlled Trial[ptyp] OR Clinical Trial, Phase
III[ptyp]).
The literature search was supplemented by a hand search for abstracts at specialized scien-
tific journals on diabetes, conferences and meetings websites. We also search for unpublished
studies at clinicaltrials.gov. In cases of incomplete data, authors were contacted to obtain addi-
tional information.
Data collection and analysis
Titles and abstracts were screened by two independent investigators (FOL and KRCA). Dupli-
cates and those that did not meet the eligibility criteria were excluded. The remaining records
were read in their entirety, and those suitable for the overview were selected. Disagreements
were solved by consensus.
Data extraction and quality assessment
Two researchers (FOL and KRCA) independently extracted data on to a standardized data-
sheet. In cases of disagreement, decisions were made by consensus. From systematic reviews,
full reference, authors, year of publication, and included clinical trials were collected. For clini-
cal trials found in the selected systematic reviews and the complementary search, we collected
full reference, authors, year of publication, characteristics of participants, number of individu-
als in the study and in each comparison arm, description of interventions in each comparison
group (including brand of insulin, frequency per day, period of day, associated bolus insulin),
and information on the selected outcomes. For continuous variables (A1C), we collected the
mean difference (SMD) between the end of the study and the baseline and the standard devia-
tion (SD) for all comparison groups. In case of missing data (i.e.SD), we tried to contact the
authors, and in cases of no reply, we assumed SD = 0.05. For dichotomous variables (general,
severe and nocturnal hypoglycemia), we used the number of episodes per person-week, which
is calculated by dividing the total number of episodes in each group by the number of persons
in each group adjusted by the time until a hypoglycemia occurs. When studies reported only
the rate of episodes per person-time (time other than a week), we disaggregated this rate to
obtain the number of episodes. For cross-over trials, we considered the A1C mean difference
in the first period and the sum of hypoglycemia episodes in both periods of analysis. For trials
that analyzed two intervention groups (i.e.: the same drug but different frequency or time of
injection), we considered the best A1C results and summed the hypoglycemia episodes of both
groups. This was different from Rossetti and colleagues [19], who yielded the hypoglycemia
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results as episodes per person-time, thus we considered the best results, as it was impossible to
sum the rates.
In the case of two or more publications from the same study, we use the most complete in
the analysis. In the case of trials reported in conference abstracts and published later, we refer
to the full text.
Quality of systematic reviews was assessed using the AMSTAR tool [20]. Quality of the evi-
dence for RCTs was assessed using Jadad modified scale [21]. The original Jadad scale is
formed by seven questions about the methodological quality of clinical trials. The modified
Jadad scale has five questions, specifically: Was the study described as randomized? Was the
method of randomization appropriate? Was the study described as double blind? Was the
method of blinding appropriate? Was there a description of withdrawals and dropouts? Clini-
cal trials with Jadad score less than 2 were excluded.
Data synthesis and analysis
A random effects meta-analysis was chosen a priori. For continuous data (A1C) we used the
difference between the end of the study and the baseline and the SD for all comparison groups
to calculate the mean difference as associate effect measure, and 95% confidence intervals by
DerSimonian & Laird method. For dichotomous data (general, severe and nocturnal hypogly-
cemia) we calculated the relative risk as the effect measure. The measure for any type of hypo-
glycemia considered in the analysis was number of episodes per person-week, so the relative
risk should be interpreted as incidence density, likewise 95% confidence intervals by the Man-
tel-Haenszel method. For dichotomous outcomes in which studies reported 0 events in one
treatment arm, we added 0.5 to the numerator and 1 to the denominator.
It is worth noting that for dichotomous outcomes the N in forest plots does not represent
the number of individuals for each group in each study, but the number of person-week.
The chi-squared test was applied to measure heterogeneity between studies at the p< 0.10
significance level. We adopted this p-value over the traditional p< 0.05 to be more conserva-
tive as low power is attributed to the chi-squared test in meta-analyses when a small number of
studies or studies of small sample size are considered [22]. The magnitude of inconsistency
was measured using I-squared (I2) statistics. An I2 of 80% was considered high heterogeneity.
For results above this threshold, we conducted sensitivity analyses to determine whether results
of some subgroups separately affected the results. We performed subgroup analyses for (a) age
group (adult and pediatric); (b) type of bolus insulin (i.e., regular human insulin, lispro, aspart
or both); and (c) brand of long-acting insulin analogue assessed (i.e., glargine or detemir).
When heterogeneity could not be explained by subgroup analysis, we performed a meta-
regression analysis, considering the variables: (a) age group; (b) type of bolus insulin; (c) brand
of long-acting insulin analogues assessed; (d) Jadad score; and (e) frequency per day of insulin
analogues; (f) if study design was cross-over or not; (g) follow-up period; (h) definition of
hypoglycemia (just for general hypoglycemia); and if study had provided standard deviation
for A1C measures.
We assessed the potential for publication bias in meta-analyses using funnel plots and
Egger’s test [23–25].
We used Stata version 11.0 for the statistical analysis.
Results
Description of included reviews
Our search for systematic reviews yielded 284 references, of which 61 were duplicates. After
removing duplicates and assessing titles and abstracts, 26 studies were identified for full-text
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reading. References excluded in this first phase were those outside the inclusion criteria. After
the screening of full texts, 11 systematic reviews [10,11,26–34] (three had been published twice
[35–37]) met the overview inclusion criteria (Fig 1). Among the 11 included studies, we found
seven original systematic reviews, four with meta-analysis [28,30–32] and three without meta-
analysis [26,33,34], two indirect comparisons [10,11] and two complete health technology
assessment studies [27,28]. Characteristics of included studies from the eligibility phase are
described in S2 Table.
Altogether, the included systematic reviews yielded 62 references of RCTs. Among them,
we included 25 in the analysis and excluded 37 that did not meet the pre-defined inclusion cri-
teria or that did not measure selected outcomes appropriately. Characteristics of included trials
are available in S3 Table. The distribution of selected clinical trials among included in the sys-
tematic reviews is presented in Table 1.
In Table 1 we can observe that none of the included systematic reviews analyzed all the
available clinical trials selected by this overview. Concerning completeness, the most complete
included systematic review was Singh et al. [31], with 21 clinical trials. This does not mean that
the reviews did not include more trials than analyzed here, but that some previously assessed
trials were not included in this overview analysis, due to the inclusion criteria.
The complementary search for clinical trials yielded 49 references just from Pubmed. After
screening of titles, abstracts and full texts, we included three references [64–66]. Twenty-one
references were excluded due to inappropriate comparison (to other comparator), 11 due to
inappropriate interventions, four of each due to unsuitable outcome and study type, and two
of each due to unsuitable population, diverse theme, and duplicates.
Methodological quality of included studies
Mean methodological quality of the 11 included systematic reviews was 7.28 (SD 3.03). Six of
them presented methodological quality ranging from 8 to 11 points out of a maximum of 11
points on the AMSTAR score (S4 Table). Almost all studies conducted a comprehensive litera-
ture search, evaluated scientific quality of the primary studies and used an appropriate method
to combine the results. However, only three studies assessed the likelihood of publication bias
[10,30,31], and only four provided lists of both included and excluded studies [27–30,32]. No
systematic review was excluded because of poor methodological quality. We considered that
the main function of systematic reviews in this overview was to attend as a source for published
clinical trials.
Quality of evidence in included reviews
Combining the clinical trials located in the systematic reviews included in this overview and
those found in the complementary search, 28 randomized clinical trials were analyzed. It is
worth noting that the overview protocol has already indicated our decision to accept the fact
that it was impossible to blind patients in these studies because the compared insulins have a
different appearance; long-acting insulin analogues are transparent and NPH insulin is a sus-
pension. Even if the authors had chosen individual pre-prepared doses, study subjects could
trigger the injection mechanism (syringe or pen) and observe the color of the medication. In
addition, a double-dummy strategy would not be recommended because it is considered
unethical in this case. We therefore decided to include studies with Jadad 2, since the lack of
blindness necessarily takes 2/5 points off the score. However, after analyzing the quality of all
the studies, it was clear that evaluators’ blindness was possible, and was successfully performed
in three of the included studies.
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Concerning the methodological quality of evidence from these studies, they were all ran-
domized and reported data for all individuals (per protocol, by intention-to-treat analysis, or
both), justifying withdrawals and dropouts. Half the clinical trials presented appropriate ran-
domization methods and just three had any level of blindness (S1 Fig).
Quantitative analysis
Meta-analysis. Among all 28 included clinical trials, allocating 8158 individuals (cross-
over studies counting twice), 4601 were randomized for insulin analogues and 3557 for NPH
insulin. Seven references were cross-over studies [40,44,55,56,58,59,66] and four were non-
inferiority trials [54,61,64,65]. Concerning quantitative analysis, the outcomes that were most
frequently analyzed were A1C and general hypoglycemia (25 trials).
In relation to A1C, the long-acting insulin analogue yielded a statistically significant reduc-
tion in A1C mean difference, considering the difference between end of study and baseline
(95% CI -0.23; -0.12; I2 99.7%) compared to NPH insulin (Fig 2A). This difference is clinically
significant, as a difference in A1C of 1.0% is already considered to be a minimal clinical thresh-
old [67].
Regarding hypoglycemia, its definition varied among the analyzed trials. Furthermore,
authors have classified hypoglycemia into many categories, such as general, overall, minor,
severe, major, symptomatic, all-day, day and nocturnal. We tried to group these categories
into understandable classes; for instance, we included general, overall, minor and all day in the
‘general’ class, severe and major in the ‘severe’ class and maintained nocturnal as a separate
Fig 1. Flowchart of the study selection process for systematic reviews.
https://doi.org/10.1371/journal.pone.0194801.g001
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class. The category “symptomatic” was assigned to the general or severe class, depending on
the applied definition in the studies.
Considering general hypoglycemia, the meta-analysis showed a statistically significant dif-
ference between the insulin analogue and NPH (RR = 0.95; 95% CI 0.91; 0.99; I2 97.5%) (Fig
2B). Although the effect was statistically significant, its magnitude and clinical significance
were small.
Data for severe hypoglycemia were usefully available from 16 studies (Fig 2C). Concerning
this outcome, the pooled estimate of all trials using the random effects model showed long-act-
ing insulin analogues did not have statistically significant results compared to NPH, revealing
a RR = 0.94 (95% CI 0.71; 1.24; I2 94.7%).
Concerning nocturnal hypoglycemia, it was available from 20 clinical trials, and the meta-
analysis results favor insulin analogues (RR 0.66; 95% CI 0.57; 0.76; I2 97.1%), meaning that
the risk of having a hypo episode was reduced (Fig 2D).
Meta-regression. Heterogeneity was impressive for all analyzed outcomes, being above
90%. Concerning A1C, the high heterogeneity was partially explained in 15.96% by methodo-
logical quality (p = 0.07) and in 9.16% by duration of the study, but not statistically significant
Fig 2. Meta-analysis of outcomes assessed in this overview: A: glycated hemoglobin—A1C; B: general hypoglycemia; C: severe hypoglycemia; D:
nocturnal hypoglycemia.
https://doi.org/10.1371/journal.pone.0194801.g002
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(p = 0.16). The heterogeneity in general hypoglycemia was explained in 26.13% by bolus insu-
lin (p = 0.01), in 13.96% by hypoglycemia definition (p = 0.10), and in 7.16% by duration of
study (p = 0.10). For nocturnal hypoglycemia, it was explained in 23.71% by crossover design
(p = 0.08) and in 13.55% by intervention brand (p = 0.08). For severe hypoglycemia, heteroge-
neity was marginally explained by age in 3.84% (p = 0.29).
Analysis of publication bias. Visual inspection of Begg’s funnel plots for hypoglycemia
endpoints (Fig 3A, 3B and 3C) showed a tendency of published trial results to have a small risk
of publication bias and the Egger’s test confirmed this direction for general (p = 0.75), severe
(p = 0.68), and nocturnal hypoglycemia (p = 0.74). However, A1C studies were very dispersed
(Fig 3D), suggesting that there is publication bias concerning this outcome, and this was con-
firmed by Egger’s test (p = 0.05).
Discussion
To the best of our knowledge, this study is the first overview of systematic reviews to assess the
efficacy of long-acting insulin compared to NPH. This study design has allowed us to carry out
the most comprehensive assessment of RCTs on this subject, filling a gap in diabetes research,
since there are many overlapping systematic reviews with contradictory recommendations.
We found evidence that long-acting insulin analogues are efficacious compared to NPH, with
estimates showing a reduction in nocturnal hypoglycemia episodes (RR 0.66) and general
hypoglycemia episodes (RR = 0.95). Further results showed a non-clinically significance reduc-
tion in A1C.
Our study used appropriate outcome measures for the outcomes included in the analysis,
like other previously published systematic reviews [28,30]. Of the 11 reviews included in this
overview, only three [28,30,31] reported the measure of hypoglycemia as episodes per person-
time, as recommended by methodological guidelines [15,68]. The other reviews
[10,11,26,29,32–34] reported hypoglycemia as the risk of having at least one event during the
study (number of people who had hypoglycemia / number of people in the study group). This
is a misconception, given that each person could experience more than one event during the
whole study follow-up. Regarding the A1C measure, three reviews [31,33,34] reported only the
comparison of the final A1C between groups. Using such a measure is not appropriate, since
the measure of interest should be how much the interventions have decreased A1C, it being
more appropriate to measure A1C difference between the end of the study and baseline [69],
as we reported.
Among the systematic reviews that assessed outcomes similar way to this overview, Vardi
and collaborators [30], in a Cochrane review, yielded comparable results to our overview con-
cerning hypoglycemia. Results showed the reduction was not statistically significant in general
hypoglycemia (OR 0.93; 95% CI 0.8; 1.08) (30). For severe hypoglycemia, for which overview
results were not statistically significant, Vardi and colleagues showed a reduction of 27% (OR
0.73; 95% CI 0.61; 0.87) and for nocturnal hypoglycemia, the results were in the same direc-
tion, with a significant reduction favouring insulin analogue (OR 0.70; 95% CI 0.63; 0.79) [30].
The results of Singh and colleagues’ review [31] are very similar to ours. Nocturnal hypoglyce-
mia was reduced in insulin analogues in 35% (OR 0.65; 95% CI 0.55;0.77) [31].
Regarding clinical trials, it is worth noting that first pilot studies are usually misunderstood.
Considering dose titration phases, the proportion of patients experiencing hypoglycemia epi-
sodes during the titration period was higher for insulin analogues than for NPH in the first tri-
als [26,38,39,70,71]. Titration could bring several biases to the interpretation of the results,
considering the use of equal doses for NPH and analogues. Thus, a substantial number of
hypos in the analogues group was noted. In conclusion, neither hypoglycemia episodes nor
Long-acting insulin analogues for type 1 diabetes
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Fig 3. Publication bias analysis by Begg’s funnel plots. A. General hypoglycemia. B. Severe hypoglycemia. C.
Nocturnal hypoglycemia. D A1C.
https://doi.org/10.1371/journal.pone.0194801.g003
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A1C in the titration period should be included in the results, according to Food and Drug
Administration recommendations: “The primary efficacy parameter should be assessed sub-
stantially after the end of the titration period (e.g., 3 months) to better reflect the steady-state
effect of the dose regimens studied” [69].
Two other major challenges when analyzing RCTs in T1D are the different ways of measur-
ing hypoglycemia and the short follow-up of studies. Regarding the definition of hypoglyce-
mia, this varies across the studies (<2.0 mmol / L,<2.8 mmol / L,<3.1 mmol / L, <4.0 mmol
/ L), contributing 14% to the heterogeneity of general hypoglycemia in our analysis. Recom-
mendations from the American Diabetes Association Workgroup on Hypoglycemia [72] and
the International Society for Pediatric and Adolescent Diabetes [73], which stratify and define
hypoglycemia appropriately, have been published. However, many of the studies, published
later than these recommendations, do not use them.
Regarding the duration of the studies, it is important to criticize studies with less than 12
weeks of follow-up. This is insufficient time to capture changes in a chronic disease, mainly
related to A1C, which is known to take three months (or 12 weeks) to present changes caused
by interventions or treatments [69,73,74].
Some authors and regulatory agencies around the world point to the lack of efficacy of insu-
lin analogues for three reasons: presentation of results based on a surrogate endpoint; absence
or small magnitude of difference in A1C; and high heterogeneity in meta-analytical analysis.
These points are controversial, as we highlight in the following paragraphs.
Regarding account A1C as a surrogate outcome, researchers in evidence-based medicine,
among them the creators of the GRADE instrument, have proposed quality criteria to evaluate
studies with surrogate outcomes. These authors [75] have stated that surrogate outcomes
should be considered relevant if they can establish a direct relationship between the surrogate
outcome and the clinical outcome it is intended to replace. The evidence of significance for
A1C occurs through the largest clinical trial in T1D and its extension, DCCT (1) and EDIC
[76]. The results of these studies established the relationship between a 1% decrease in A1C
and at least a 43% decrease in microvascular complications. Such reduction of 1% is interna-
tionally accepted as clinically significant [69].
Regarding the small magnitude of the effect of long-acting insulin analogues in A1C, it is
important to remember that its primary role in the algorithm for treating T1D is to improve
glucose control and decrease the risk of hypoglycemia. Therefore, since A1C is an average of
the glycaemia of the last three months, we can see the fact that these insulins decrease the
occurrence of hypoglycemia (lower limit of the mean) as positive, providing maintenance or
even little improvement of A1C [74], as occurs in this overview.
Heterogeneity was high and significant, being greater than 90% in all outcomes considered
in our overview. The variables that most explained the heterogeneity were bolus insulin (26%)
and definition of hypo (14%) for general hypoglycemia, cross-over design (23%) and interven-
tion brand (13%) for nocturnal hypoglycemia, and Jadad score (16%) for A1C. Two other fac-
tors have influenced the inconsistency of the results, but their impact was not clear: i) the fact
that the rate of episodes per person-time was calculated for most of the studies, and the
absence of standard deviation estimates for A1C in some meta-analysis. High heterogeneity
was common among the systematic reviews analyzed in this overview [10,30,31]. It is worth
noting that a portion of the heterogeneity could not be explained by the variables studied in
this overview.
Some limitations of our study should be acknowledged. First, we did not include insulin
degludec in our overview. Although it is one the most recent long-acting insulins on the mar-
ket, we did not identify any study comparing it to NPH. Second, we excluded some conference
abstracts due to the low methodological quality of the reports, often with insufficient data for
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analysis. Third, when we searched for new RCTs published after the last systematic review
included in our overview, we only searched Pubmed, i.e. we did not carry out a full systematic
review of RCTs.
To date, some indirect comparison analyses have been performed [10,11,77], but none of
them included all the therapeutic options available in terms of basal insulins. Thus, as a recom-
mendation for future research, we suggest performing indirect comparison analysis or net-
work meta-analysis including all basal profile insulins, such as NPH, glargine, detemir,
degludec [78], lispro protamine suspension [79], peglispro [80], glargine 300 U/ml [81], pre-
mixed [82], and biosimilars insulins [83]. This latter may represent hope for population access
to better insulins at an affordable cost for public health systems in developing countries [84–
87].
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